how do you use digital currency People searches

The European Central Bank expects inflation to cool down faster. It is reported that the European Central Bank now expects inflation to cool down slightly faster than the forecast in September. It currently predicts that the average inflation rate in 2024 and 2025 will be 2.4% and 2.1% respectively, compared with the previous forecast of 2.5% and 2.2% respectively. In the statement, the European Central Bank also said: "The anti-inflation process is on the right track."European Central Bank President Lagarde: The European Central Bank did not discuss neutral interest rates this week. Many things will become clear in the next few months, not in the next few weeks.Royal Bank of Canada: The European Central Bank may move towards negative real interest rate. Royal Bank of Canada BlueBay Asset Management said that the European Central Bank may cut the interest rate below 2% next year, which the agency estimated to be a short-term neutral interest rate. Kaspar Hense, senior portfolio manager of the institution, said in a report that the core inflation rate is expected to be around 2.5% in the first half of 2025, which means that the real interest rate will be negative. He said that under the influence of unfavorable factors such as trade, continuous competitive pressure from other countries and financial problems, this should play a moderate supporting role in the economy.

Trump: If Kennedy Jr. takes action, he will have a "big discussion" on ending the children's vaccination program.Market News: The Director of the Federal Aviation Administration will step down on January 20th.NATO Secretary General Rutte: We will need to spend far more than 2% of GDP on national defense.

Lagarde, President of the European Central Bank: The Transmission Protection Tool (TPI) was not discussed.European Central Bank President Lagarde: The uncertainty brought by the next US administration is not within the forecast benchmark.Baiyang Pharmaceutical Group signed an agreement with Peking University Hospital. On December 12, Baiyang Pharmaceutical Group signed a cooperation agreement with Peking University No.1 Hospital, and obtained the exclusive right to patent, clinical development and registration, production and marketing of "targeted integrin small molecule inhibitor" in Peking University Hospital.